drugset / Trial / NCT07314346

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone

NCT07314346

Phase 1 Recruiting 32 enrolled Atea Pharmaceuticals, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

Drug-drug interaction study between Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone

Timeline

Start
2025-01-07
Primary completion
2026-08
Completion
2026-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Bemnifosbuvir/Ruzasvir Unknown 180 mg Oral
Subject Bemnifosbuvir/Ruzasvir Unknown 550 mg Oral
Subject Buprenorphine/Naloxone Unknown 6 mg
Subject Buprenorphine/Naloxone Unknown 24 mg
Subject Methadone Other / unclassified

Indications

No indication recorded.